

# Angelalign (6699 HK)

## Domestic clear aligner leader accelerating global expansion

Founded in 2003, Angelalign is a leading provider of clear aligner treatment solutions in China. For four consecutive years since 2021, Angelalign has maintained its No.1 market share in China's clear aligner market. Angelalign achieved a robust revenue CAGR of 23.8% (in USD terms based on historical exchange rates) from 2019 to 2024. We expect Angelalign to benefit from an improving domestic competitive landscape and rapid overseas expansion, sustaining strong revenue growth with a CAGR of 18.0% for 2024-27E. Based on an SOTP valuation, we derive a TP of HK\$69.55 per share. Initiate coverage on the company with BUY.

- Steady growth in China with strengthened leadership position.** China has a large malocclusion patient base. Rising incomes and aesthetic awareness are expected to boost clear aligner penetration. Angelalign has solidified its No.1 position since 2021 with a 42% domestic market share in 2023, according to CIC. Macro headwinds slowed domestic market growth, resulting in smaller brand exits and likely further share concentration among leaders. With comprehensive portfolios, Angelalign has expanded to lower-tier cities and children/adolescents market, which has driven its solid growth despite macro pressures. In 2024, its domestic case volume increased by 3.2% YoY. Short-term margin pressure from product and channel mixes persists, yet process optimization and cost management have kept domestic profitability stable. We think the clear aligner industry exhibits strong brand stickiness. Outstanding product quality and clinical services enable Angelalign to build deep doctor partnerships, positioning it for further market share expansion.
- Rapid globalization with improving profitability.** The global clear aligner market reached US\$6.5bn in 2024 and is expected to reach US\$32bn by 2030E (30.7% CAGR, according to Grand View Research). Angelalign has rapidly expanded overseas since 2022. In 2024, Angelalign's overseas cases achieved 140,700, generating revenue of US\$81mn, accounting for 30% of total revenue. Through a "localized operations + M&A" model, Angelalign has established a global supply chain and local teams, rapidly expanding in key markets such as Europe and Brazil. We think Angelalign has largely completed the high-investment customer acquisition phase with profitability, ASP, and gross margin trending upward. We expect overseas business to continue to be Angelalign's long-term growth driver.
- Technology innovation and digitalization create high competitive barriers.** Angelalign maintains high R&D investment, and owns a comprehensive product portfolio and an advanced digital orthodontic platform. Its iOrtho platform and digital tools improve doctor efficiency and simplify complex case management, which enhance doctor loyalty. Technology barriers, product innovation, and digital capabilities not only reinforce Angelalign's leadership in China but also provide core competitiveness for global expansion.
- Initiate at BUY with TP of HK\$69.55.** We expect Angelalign to maintain strong growth in overseas markets, and forecast a 42.8% overseas revenue CAGR (2024-27E). We project a 3.3% domestic revenue CAGR (2024-27E) with stable operating margins. Based on our SOTP valuation, we assign 18x 2025E P/E to the mature domestic business and 6x 2025E P/S to the rapidly expanding overseas business, deriving a target price of HK\$69.55.

### Earnings Summary

(YE 31 Dec)	FY23A	FY24A	FY25E	FY26E	FY27E
Revenue (US\$ mn)	210	269	320	377	442
YoY growth (%)	16.2	28.2	19.1	17.9	17.1
Adjusted net profit (US\$ mn)	26	27	27	39	55
YoY growth (%)	(16.0)	2.9	2.2	40.3	42.4
EPS (Adjusted) (US\$)	0.16	0.16	0.16	0.23	0.32
P/E (x)	154.1	95.9	96.9	53.5	31.8
P/E (Adjusted) (x)	44.5	43.3	42.8	30.5	21.4

Source: Company data, Bloomberg, CMBIGM estimates

**BUY (Initiate)**

**Target Price** HK\$69.55  
**Up/Downside** 29.0%  
**Current Price** HK\$53.90

### China Healthcare

#### Cathy WANG

(852) 3916 1729

cathywang@cmbi.com.hk

#### Jill WU, CFA

(852) 3900 0842

jillwu@cmbi.com.hk

### Stock Data

Mkt Cap (HK\$ mn)	9,164.4
Avg 3 mths t/o (HK\$ mn)	58.2
52w High/Low (HK\$)	76.30/46.65
Total Issued Shares (mn)	170.0

Source: FactSet

### Shareholding Structure

CareCapital Orthotech Limited	51.3%
Shore Lead Limited	12.6%


Source: HKEx

### Share Performance

	Absolute	Relative
1-mth	10.8%	1.4%
3-mth	-8.0%	-11.3%
6-mth	-11.8%	-26.9%

Source: FactSet

### 12-mth Price Performance



Source: FactSet

## Earnings forecasts and valuation

Figure 1: Revenue forecasts (2023-2027E) - by segment/region

		2023	2024	2025E	2026E	2027E
<b>By segment</b>						
Clear aligner treatment solutions	Revenue (US\$m)	182	180	180	179	183
	YoY	6.0%	-1.3%	0.0%	-0.1%	1.9%
Sales of clear aligners	Revenue (US\$m)	15	74	123	177	235
	YoY	1651.4%	397.8%	65.8%	44.2%	32.6%
Sales of other products	Revenue (US\$m)	10	13	15	18	21
	YoY	-14.9%	25.7%	20.0%	19.0%	18.0%
Other services	Revenue (US\$m)	3	2	3	3	3
	YoY	14.1%	-4.9%	10.0%	9.0%	8.0%
<b>By region</b>						
Mainland China	Case volume	212,000	218,700	225,480	232,244	243,856
	YoY	15.3%	3.2%	3.1%	3.0%	5.0%
	Revenue (US\$m)	189	188	198	201	207
	YoY	5.5%	-0.4%	5.0%	1.5%	3.4%
Overseas	Case volume	33,000	140,700	211,050	295,470	384,111
	YoY		326.4%	50.0%	40.0%	30.0%
	Revenue (US\$m)	21	81	123	177	235
	YoY	1651.4%	290.4%	52.3%	44.2%	32.6%
<b>Total revenue (US\$m)</b>		<b>210</b>	<b>269</b>	<b>320</b>	<b>377</b>	<b>442</b>
YoY		16.2%	28.2%	19.1%	17.9%	17.1%

Source: Angelalign, CMBIGM estimates

Note: 1) Revenue generated from clear aligner treatment solutions mainly represents the revenue generated from provision of clear aligner treatment solutions services to clients in the China market. Revenue generated from sales of clear aligners mainly represents the revenue generated from sales of clear aligners to clients in the non-China global markets. 2) For 2025E-2027E, revenue from mainland China is estimated based on revenue from clear aligner treatment solutions, sales of other products, and other services. Overseas revenue is estimated based on revenue from sales of clear aligners.

Figure 2: CMBIGM estimates vs consensus

(US\$m)	CMBI			Consensus			Diff. (%)		
	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
Revenue	320	377	442	301	363	391	6.3%	4.0%	13.1%
Gross profit	190	228	270	183	221	243	3.5%	3.0%	10.9%
Operating profit	6	18	34	7	18	49	-22.8%	-0.4%	-30.6%
Net profit	12	22	37	16	28	41	-25.8%	-21.7%	-9.6%
EPS (US\$)	0.07	0.13	0.22	0.10	0.17	-	-25.7%	-23.2%	-
Gross margin	59.24%	60.34%	61.08%	60.81%	60.93%	62.28%	-1.56ppt	-0.59ppt	-1.2ppt
Operating profit margin	1.80%	4.68%	7.74%	2.48%	4.89%	12.61%	-0.68ppt	-0.21ppt	-4.87ppt
Net margin	3.78%	5.81%	8.35%	5.42%	7.72%	10.44%	-1.63ppt	-1.91ppt	-2.09ppt

Source: Bloomberg, CMBIGM estimates

The development stages of Angelalign's domestic and overseas businesses differs. The domestic business is mature, with a solid industry position and stable profitability. The overseas business is still in the incubation phase, characterized by significant early-stage investments in capacity building and market promotion, with a smaller revenue base but robust growth. Therefore, we apply P/E valuation to its domestic business and P/S to its overseas operations.

### Domestic business

We expect the profitability of Angelalign's domestic business to remain stable, with operating profit increasing to US\$28mn/ US\$28mn/ US\$29mn in 2025E/26E/27E. Assuming a 15% tax rate, after-tax operating profit is estimated at US\$24mn/ US\$24mn/ US\$25mn in 2025E/26E/27E. We assign an 18x 2025E P/E, in line with Align Technology, corresponding to a market capitalization of US\$429mn.

**Figure 3: Operating profit forecast of domestic business**

(US\$mn)	2023	2024	2025E	2026E	2027E
<b>Mainland China</b>					
Operating profit	27	27	28	28	29
Operating profit margin	14.3%	14.3%	14.2%	14.1%	14.0%
Tax rate	20.3%	14.2%	15.0%	15.0%	15.0%
Tax	5	4	4	4	4
Post-tax operating profit	22	23	24	24	25

Source: Company data, CMBIGM estimates

Note: Operating profit = Gross profit – (selling expenses + R&D expenses + administrative expenses)

### Overseas business

We expect Angelalign's overseas business to maintain strong growth, with revenue growing to US\$123mn/ US\$177mn/ US\$235mn in 2025E/26E/27E. We assign a 6x 2025E P/S multiple, in line with the peer average, corresponding to a market capitalization of US\$736mn.

**Figure 4: Overseas revenue forecast**

(US\$mn)	2023	2024	2025E	2026E	2027E
<b>Overseas</b>					
Revenue	21	81	123	177	235
Operating profit	-31	-31	-32	-19	-3
Operating profit margin	-149.1%	-38.7%	-26.4%	-11.0%	-1.3%

Source: Company data, CMBIGM estimates

Note: Operating profit = Gross profit – (selling expenses + R&D expenses + administrative expenses)

**Figure 5: Peer comparison**

Company	Ticker	Rating	Market Cap (US\$m)	Price (LC)	P/E (x)		P/S (x)	
					FY25E	FY26E	FY25E	FY26E
<b>Overseas</b>								
Alcon	ALC US	NA	47,367	94.8	29.4	24.8	4.6	4.2
Align Technology	ALGN US	NA	13,700	189.0	18.4	16.8	3.3	3.1
Straumann	STMN SW	NA	21,123	111.8	32.3	28.2	6.6	6.0
Envista	NVST US	NA	3,144	18.6	18.6	16.2	1.2	1.2
Stryker	SYK US	NA	148,311	388.1	29.0	26.2	6.0	5.5
Boston Scientific	BSX US	NA	152,191	102.9	35.3	31.2	7.8	7.1
Dexcom	DXCM US	NA	33,349	85.1	42.6	34.5	7.2	6.3
STAAR Surgical	STAA US	NA	1,004	20.3	NA	65.8	3.9	3.1
<b>Average</b>					<b>29.4</b>	<b>30.5</b>	<b>5.1</b>	<b>4.6</b>
<b>H &amp; A share</b>								
CardioFlow	2160 HK	NA	263	0.9	NA	25.4	3.7	3.0
Zylox-Tonbridge	2190 HK	NA	776	18.6	34.9	23.2	5.2	3.9
Peijia Medical	9996 HK	NA	448	5.2	NA	438.8	4.0	3.1
MicroPort NeuroScientific	2172 HK	NA	812	11.0	20.6	16.4	6.5	5.2
Ovctek	300595 CH	NA	1,887	15.2	19.4	17.4	6.5	5.8
Yuyue Medical	002223 CH	NA	4,946	35.6	16.9	14.6	4.1	3.6
Eyebright Medical	688050 CH	NA	2,082	79.1	31.2	24.3	8.3	6.5
Apt Medical	688617 CH	NA	5,376	399.0	42.9	32.8	14.4	11.1
<b>Average</b>					<b>27.6</b>	<b>74.1</b>	<b>6.6</b>	<b>5.3</b>
<b>Overall average</b>					<b>28.6</b>	<b>52.3</b>	<b>5.8</b>	<b>4.9</b>

Source: Bloomberg, CMBIGM, as of May 13, 2025

**Figure 6: Angelalign: SOTP valuation**

	2025E net profit (US\$m)	2025E revenue (US\$m)	2025E PE (x)	2025E PS (x)	Valuation to Angelalign (US\$m)	As % of total valuation	Per share valuation (HK\$)
Domestic business	24		18x		429	28.3	19.7
Overseas business		123		6x	736	48.5	33.8
Net cash					351	23.1	16.1
<b>Valuation of Angelalign</b>					<b>1,516</b>		
USDHKD					7.8		
<b>Valuation of Angelalign (HK\$m)</b>					<b>11,826</b>		
# of shares (mn)					<b>170</b>		
<b>Valuation per share – Angelalign (HK\$)</b>					<b>69.55</b>		

Source: Company data, CMBIGM estimates

## Investment Risks

- 1) Underperformance in overseas market expansion;
- 2) Significant investment in overseas markets lead to pressure on profitability;
- 3) Intensified competition in the domestic market;
- 4) The macroeconomic environment continues to impact domestic market demand.

## Financial Summary

INCOME STATEMENT	2023A	2024A	2025E	2026E	2027E
YE 31 Dec (US\$ mn)					
<b>Revenue</b>	<b>210</b>	<b>269</b>	<b>320</b>	<b>377</b>	<b>442</b>
Cost of goods sold	(79)	(101)	(131)	(150)	(172)
<b>Gross profit</b>	<b>131</b>	<b>168</b>	<b>190</b>	<b>228</b>	<b>270</b>
Selling expense	(70)	(105)	(120)	(136)	(150)
Admin expense	(40)	(46)	(51)	(57)	(62)
R&D expense	(25)	(21)	(22)	(26)	(32)
Others	(1)	(0)	0	0	0
Other income	5	12	10	9	8
Other expense	0	(0)	0	0	0
Other gains/(losses)	(4)	(2)	0	0	0
<b>Operating profit</b>	<b>(4)</b>	<b>6</b>	<b>6</b>	<b>18</b>	<b>34</b>
Net Interest income/(expense)	12	5	6	6	7
Others	0	(0)	0	0	0
<b>Pre-tax profit</b>	<b>9</b>	<b>12</b>	<b>12</b>	<b>23</b>	<b>41</b>
Income tax	(2)	(2)	(2)	(4)	(6)
<b>After tax profit</b>	<b>7</b>	<b>10</b>	<b>10</b>	<b>20</b>	<b>35</b>
Minority interest	(1)	(2)	(2)	(2)	(2)
<b>Attributable net profit</b>	<b>8</b>	<b>12</b>	<b>12</b>	<b>22</b>	<b>37</b>
<b>Adjusted net profit</b>	<b>26</b>	<b>27</b>	<b>27</b>	<b>39</b>	<b>55</b>
Gross dividends	24	8	7	13	22

BALANCE SHEET	2023A	2024A	2025E	2026E	2027E
YE 31 Dec (US\$ mn)					
<b>Current assets</b>	<b>525</b>	<b>492</b>	<b>516</b>	<b>550</b>	<b>599</b>
Cash & equivalents	380	227	239	261	298
Restricted cash	0	0	0	0	0
Account receivables	26	36	47	55	64
Inventories	13	18	21	24	27
ST bank deposits	0	112	112	112	112
Financial assets at FVTPL	106	98	98	98	98
Other current assets	0	0	0	0	0
<b>Non-current assets</b>	<b>147</b>	<b>186</b>	<b>220</b>	<b>232</b>	<b>238</b>
PP&E	61	75	109	122	129
Right-of-use assets	14	18	16	15	13
Deferred income tax	5	7	7	7	7
Investment in JVs & assos	3	5	5	5	5
Intangibles	23	18	19	20	21
Financial assets at FVTPL	36	39	39	39	39
Other non-current assets	6	24	24	24	24
<b>Total assets</b>	<b>672</b>	<b>678</b>	<b>736</b>	<b>782</b>	<b>838</b>
<b>Current liabilities</b>	<b>124</b>	<b>128</b>	<b>171</b>	<b>196</b>	<b>225</b>
Amounts due to related parties	0	0	0	0	0
Short-term borrowings	2	3	3	3	3
Account payables	53	63	75	86	98
Other current liabilities	3	1	1	1	1
Lease liabilities	2	4	4	4	4
Contract liabilities	64	57	88	102	119
<b>Non-current liabilities</b>	<b>66</b>	<b>70</b>	<b>70</b>	<b>70</b>	<b>70</b>
Long-term borrowings	1	0	0	0	0
Deferred income	5	4	4	4	4
Other non-current liabilities	61	65	65	65	65
<b>Total liabilities</b>	<b>190</b>	<b>198</b>	<b>241</b>	<b>266</b>	<b>294</b>
Share capital	0	0	0	0	0
Others	507	492	504	518	533
Other reserves	(36)	(18)	(13)	(4)	11
<b>Total shareholders equity</b>	<b>471</b>	<b>474</b>	<b>491</b>	<b>514</b>	<b>544</b>
Minority interest	10	6	4	2	(0)
<b>Total equity and liabilities</b>	<b>672</b>	<b>678</b>	<b>736</b>	<b>782</b>	<b>838</b>

<b>CASH FLOW</b>	<b>2023A</b>	<b>2024A</b>	<b>2025E</b>	<b>2026E</b>	<b>2027E</b>
<b>YE 31 Dec (US\$ mn)</b>					
<b>Operating</b>					
Profit before taxation	9	12	12	23	41
Depreciation & amortization	12	16	12	14	14
Tax paid	(7)	(7)	(2)	(4)	(6)
Change in working capital	7	1	30	14	16
Others	1	(4)	0	3	4
<b>Net cash from operations</b>	<b>22</b>	<b>17</b>	<b>53</b>	<b>50</b>	<b>69</b>
<b>Investing</b>					
Capital expenditure	(13)	(27)	(45)	(25)	(20)
Acquisition of subsidiaries/ investments	0	(3)	0	0	0
Others	(125)	(109)	13	11	11
<b>Net cash from investing</b>	<b>(139)</b>	<b>(139)</b>	<b>(32)</b>	<b>(14)</b>	<b>(9)</b>
<b>Financing</b>					
Dividend paid	(15)	(24)	(7)	(13)	(22)
Net borrowings	(3)	1	0	0	0
Proceeds from share issues	0	0	0	0	0
Others	(8)	(6)	(1)	(1)	(1)
<b>Net cash from financing</b>	<b>(26)</b>	<b>(28)</b>	<b>(8)</b>	<b>(14)</b>	<b>(23)</b>
<b>Net change in cash</b>					
Cash at the beginning of the year	524	380	227	239	261
Exchange difference	(1)	(2)	0	0	0
<b>Cash at the end of the year</b>	<b>380</b>	<b>227</b>	<b>239</b>	<b>261</b>	<b>298</b>
<b>GROWTH</b>	<b>2023A</b>	<b>2024A</b>	<b>2025E</b>	<b>2026E</b>	<b>2027E</b>
<b>YE 31 Dec</b>					
Revenue	16.2%	28.2%	19.1%	17.9%	17.1%
Gross profit	17.2%	28.7%	12.8%	20.0%	18.5%
Operating profit	na	na	(8.0%)	206.0%	93.5%
EBITDA	(78.8%)	164.6%	(16.7%)	72.4%	54.9%
Net profit	(75.0%)	60.9%	0.1%	81.0%	68.2%
Adj. net profit	(16.0%)	2.9%	2.2%	40.3%	42.4%
<b>PROFITABILITY</b>	<b>2023A</b>	<b>2024A</b>	<b>2025E</b>	<b>2026E</b>	<b>2027E</b>
<b>YE 31 Dec</b>					
Gross profit margin	62.4%	62.6%	59.2%	60.3%	61.1%
Operating margin	(1.9%)	2.3%	1.8%	4.7%	7.7%
EBITDA margin	3.9%	8.1%	5.7%	8.3%	11.0%
Adj. net profit margin	12.5%	10.0%	8.6%	10.2%	12.4%
Return on equity (ROE)	0.4%	2.6%	2.5%	4.4%	7.0%
<b>GEARING/LIQUIDITY/ACTIVITIES</b>	<b>2023A</b>	<b>2024A</b>	<b>2025E</b>	<b>2026E</b>	<b>2027E</b>
<b>YE 31 Dec</b>					
Net debt to equity (x)	(0.8)	(0.7)	(0.7)	(0.7)	(0.8)
Current ratio (x)	4.2	3.8	3.0	2.8	2.7
Receivable turnover days	43.1	52.5	53.0	53.0	53.0
Inventory turnover days	68.5	57.7	58.0	58.0	58.0
Payable turnover days	243.5	211.3	210.0	209.0	208.0
<b>VALUATION</b>	<b>2023A</b>	<b>2024A</b>	<b>2025E</b>	<b>2026E</b>	<b>2027E</b>
<b>YE 31 Dec</b>					
P/E	154.1	95.9	96.9	53.5	31.8
Adjusted P/E	44.5	43.3	42.8	30.5	21.4
P/B	2.4	2.4	2.4	2.3	2.2
Div yield (%)	2.1	0.7	0.6	1.1	1.9

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

# Disclosures & Disclaimers

## Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

## CMBIGM Ratings

**BUY** : Stock with potential return of over 15% over next 12 months  
**HOLD** : Stock with potential return of +15% to -10% over next 12 months  
**SELL** : Stock with potential loss of over 10% over next 12 months  
**NOT RATED** : Stock is not rated by CMBIGM

**OUTPERFORM** : Industry expected to outperform the relevant broad market benchmark over next 12 months  
**MARKET-PERFORM** : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months  
**UNDERPERFORM** : Industry expected to underperform the relevant broad market benchmark over next 12 months

## CMB International Global Markets Limited

**Address:** 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

**CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)**

## Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

### For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

### For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

### For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.